TABLE 3.
Omicron RBD mutations with reduced neutralization by therapeutic antibodiesa
| RBD mutation | Therapeutic Ab (alternate name) |
||||||
|---|---|---|---|---|---|---|---|
| Casirivimab (REGN10933) | Imadevimab (REGN10987) | Bamlanivimab (LY-CoV555) | Etesevimab (LY-CoV016) | Sotrovimab (VIR-7831) | Tixagevimab (CoV2-2196) | Cilgavimab (CoV2-2130) | |
| G339D | |||||||
| S371L | |||||||
| S373P | |||||||
| S375F | |||||||
| K417N | |||||||
| N440K | |||||||
| G446S | |||||||
| S477N | |||||||
| T478K | |||||||
| E484A | |||||||
| Q493R | |||||||
| G496S | |||||||
| Q498R | |||||||
| N501Y | |||||||
| Y505H | |||||||
a
The results observed for Regeneron MAbs (Casirivimab and Imdevimab), Eli Lilly MAbs (Bamlanivimab and Etesevimab), Sotrovimab, and AstraZeneca MAbs (Cilgavimab and Tixagevimab) are shown. Key residues that confer resistance to the antibody are highlighted by dark gray shading.